{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:57:35Z","timestamp":1792447055870,"version":"4.5.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:p>Incorporation of molecular classification into clinicopathologic assessment of endometrial carcinoma (EC) improves risk stratification. Four EC molecular subtypes, as identified by The Cancer Genome Atlas, can be diagnosed through a validated algorithm <jats:italic toggle=\"yes\">Pro<\/jats:italic>active <jats:italic toggle=\"yes\">M<\/jats:italic>olecular R<jats:italic toggle=\"yes\">is<\/jats:italic>k Classifier for <jats:italic toggle=\"yes\">E<\/jats:italic>ndometrial Cancer (ProMisE) using p53 and mismatch repair (MMR) protein immunohistochemistry (IHC), and DNA polymerase epsilon (<jats:italic toggle=\"yes\">POLE)<\/jats:italic> mutational testing. Cost and access are major barriers to universal testing, particularly <jats:italic toggle=\"yes\">POLE<\/jats:italic> analysis. We assessed a selective ProMisE algorithm (ProMisE-S): p53 and MMR IHC on all EC\u2019s with <jats:italic toggle=\"yes\">POLE<\/jats:italic> testing restricted to those with abnormal MMR or p53 IHC (to identify POLEmut EC with secondary abnormalities in MMR and\/or p53) and those with high-grade or non-endometrioid morphology, stage &gt;IA or presence of lymphovascular space invasion (so as to avoid testing on the lowest risk tumors). We retrospectively compared the known ProMisE molecular classification to ProMisE-S in 912 EC. We defined a group of \u201cvery low-risk\u201d EC (G1\/G2, endometrioid, MMR-proficient, p53 wild-type, stage IA, no lymphovascular space invasion) in whom <jats:italic toggle=\"yes\">POLE<\/jats:italic> testing will not impact on patient care; using ProMisE-S, <jats:italic toggle=\"yes\">POLE<\/jats:italic> testing would not be required in 55% of biopsies and 38% of all EC\u2019s, after evaluation of the hysterectomy specimen, in a population-based cohort. \u201cVery low-risk\u201d endometrioid EC with unknown <jats:italic toggle=\"yes\">POLE<\/jats:italic> status showed excellent clinical outcomes. Fifteen of 166 (9%) of all p53abn EC showed G1\/G2 endometrioid morphology, supporting the potential value of universal p53 IHC. The addition of molecular testing changed the risk category in 89\/896 (10%) EC\u2019s. In routine practice, <jats:italic toggle=\"yes\">POLE<\/jats:italic> testing could be further restricted to only those patients in whom this would alter adjuvant therapy recommendations.<\/jats:p>","DOI":"10.1097\/pgp.0000000000000898","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T18:51:59Z","timestamp":1675363919000},"page":"353-363","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":30,"title":["Targeted Molecular Testing in Endometrial Carcinoma: Validation of a Clinically Driven Selective ProMisE Testing Protocol"],"prefix":"10.1097","volume":"42","author":[{"given":"Aline","family":"Talhouk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Jamieson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma J.","family":"Crosbie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Grube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kommoss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Blake","family":"Gilks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica N.","family":"McAlpine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveena","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,10,5]]},"reference":[{"key":"R1-20250802","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0090-8258(83)90111-7","article-title":"Two pathogenetic types of endometrial carcinoma","volume":"15","author":"Bokhman","year":"1983","journal-title":"Gynecol Oncol"},{"key":"R2-20250802","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1053\/j.semdp.2010.09.003","article-title":"Endometrial carcinomas with ambiguous features","volume":"27","author":"Soslow","year":"2010","journal-title":"Semin Diagn Pathol"},{"key":"R3-20250802","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/his.12029","article-title":"High-grade endometrial carcinomas\u2014strategies for typing","volume":"62","author":"Soslow","year":"2013","journal-title":"Histopathology"},{"key":"R4-20250802","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1097\/PAS.0b013e31827f576a","article-title":"Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma","volume":"37","author":"Gilks","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"R5-20250802","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"R6-20250802","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/bjc.2015.190","article-title":"A clinically applicable molecular-based classification for endometrial cancers","volume":"113","author":"Talhouk","year":"2015","journal-title":"Br J Cancer"},{"key":"R7-20250802","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cncr.30496","article-title":"Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer","volume":"123","author":"Talhouk","year":"2017","journal-title":"Cancer"},{"issue":"suppl 1","key":"R8-20250802","first-page":"1180","article-title":"Validation of ProMisE molecular classifier in a large population-based series: a new era in endometrial carcinoma diagnosis and treatment","volume":"41","author":"Kommoss","year":"2018","journal-title":"Oncol Res Treat"},{"key":"R9-20250802","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/path.5373","article-title":"Clinicopathological and molecular characterisation of \u201cmultiple-classifier\u201d endometrial carcinomas","volume":"250","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J Pathol"},{"key":"R10-20250802","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/path.5372","article-title":"Interpretation of somatic POLE mutations in endometrial carcinoma","volume":"250","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J Pathol"},{"key":"R11-20250802","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1002\/cncr.33516","article-title":"Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: an individual patient data meta-analysis","volume":"127","author":"McAlpine","year":"2021","journal-title":"Cancer"},{"key":"R13-20250802","doi-asserted-by":"crossref","first-page":"170","DOI":"10.6004\/jnccn.2018.0006","article-title":"Uterine neoplasms, version 1.2018: clinical practice guidelines in oncology","volume":"16","author":"Koh","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"R14-20250802","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.radonc.2020.11.018","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma","volume":"154","author":"Concin","year":"2021","journal-title":"Radiother Oncol"},{"key":"R16-20250802","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ygyno.2019.08.019","article-title":"TCGA molecular groups of endometrial cancer: pooled data about prognosis","volume":"155","author":"Raffone","year":"2019","journal-title":"Gynecol Oncol"},{"key":"R17-20250802","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/PAS.0000000000001020","article-title":"Molecular classification of grade 3 endometrioid endometrial cancers identifies distinct prognostic subgroups","volume":"42","author":"Bosse","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"R18-20250802","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1200\/JCO.20.00549","article-title":"Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy","volume":"38","author":"Leon-Castillo","year":"2020","journal-title":"J Clin Oncol"},{"key":"R19-20250802","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/path.5034","article-title":"The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses","volume":"244","author":"McAlpine","year":"2018","journal-title":"J Pathol"},{"key":"R20-20250802","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ygyno.2016.12.015","article-title":"Molecular approaches for classifying endometrial carcinoma","volume":"145","author":"Piulats","year":"2017","journal-title":"Gynecol Oncol"},{"key":"R21-20250802","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/PGP.0000000000000654","article-title":"Interlaboratory concordance of ProMisE molecular classification of endometrial carcinoma based on endometrial biopsy specimens","volume":"39","author":"Plotkin","year":"2020","journal-title":"Int J Gynecol Pathol"},{"key":"R22-20250802","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ygyno.2016.07.090","article-title":"Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: Earlier prognostic information to guide treatment","volume":"143","author":"Talhouk","year":"2016","journal-title":"Gynecol Oncol"},{"key":"R24-20250802","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1136\/ijgc-2020-002256","article-title":"P53abn Endometrial Cancer: Understanding the most aggressive endometrial cancers in the era of molecular classification","volume":"31","author":"Jamieson","year":"2021","journal-title":"Int J Gynecol Cancer"},{"key":"R26-20250802","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/his.14015","article-title":"Incorporation of molecular characteristics into endometrial cancer management","volume":"76","author":"Vermij","year":"2020","journal-title":"Histopathology"},{"key":"R27-20250802","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/cjp2.243","article-title":"Selection of endometrial carcinomas for p53 immunohistochemistry based on nuclear features","volume":"8","author":"Kang","year":"2022","journal-title":"J Pathol Clin Res"},{"key":"R28-20250802","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/modpathol.2017.15","article-title":"CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence","volume":"30","author":"Kurnit","year":"2017","journal-title":"Mod Pathol"},{"key":"R29-20250802","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/s41379-019-0220-1","article-title":"Impact of TP53 immunohistochemistry on the histological grading system for endometrial endometrioid carcinoma","volume":"32","author":"Yano","year":"2019","journal-title":"Mod Pathol"}],"container-title":["International Journal of Gynecological Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PGP.0000000000000898","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:01:12Z","timestamp":1754161272000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PGP.0000000000000898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,5]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/pgp.0000000000000898","relation":{},"ISSN":["0277-1691"],"issn-type":[{"value":"0277-1691","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,5]]}}}